Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems.
anisotropic nanogel
complex coacervation
dual loading
nanocarriers
nucleic acid vaccine
physical cross-linking
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
13 Nov 2021
13 Nov 2021
Historique:
received:
03
09
2021
revised:
08
11
2021
accepted:
10
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Co-delivery of different species of protein-encoding polynucleotides, e.g., messenger RNA (mRNA) and plasmid DNA (pDNA), using the same nanocarrier is an interesting topic that remains scarcely researched in the field of nucleic acid delivery. The current study hence aims to explore the possibility of the simultaneous delivery of mRNA (mCherry) and pDNA (pAmCyan) using a single nanocarrier. The latter is based on gelatin type A, a biocompatible, and biodegradable biopolymer of broad pharmaceutical application. A core-shell nanostructure is designed with a thermally stabilized gelatin-pDNA coacervate in its center. Thermal stabilization enhances the core's colloidal stability and pDNA shielding effect against nucleases as confirmed by nanoparticle tracking analysis and gel electrophoresis, respectively. The stabilized, pDNA-loaded core is coated with the cationic peptide protamine sulfate to enable additional surface-loading with mRNA. The dual-loaded core-shell system transfects murine dendritic cell line DC2.4 with both fluorescent reporter mRNA and pDNA simultaneously, showing a transfection efficiency of 61.4 ± 21.6% for mRNA and 37.6 ± 19.45% for pDNA, 48 h post-treatment, whereas established commercial, experimental, and clinical transfection reagents fail. Hence, the unique co-transfectional capacity and the negligible cytotoxicity of the reported system may hold prospects for vaccination among other downstream applications.
Identifiants
pubmed: 34834339
pii: pharmaceutics13111924
doi: 10.3390/pharmaceutics13111924
pmc: PMC8619316
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Higher Education
ID : Egyptian Mission sector full PhD scholarship
Références
Immunity. 2005 Aug;23(2):165-75
pubmed: 16111635
Cancer Res. 2002 Mar 1;62(5):1271-4
pubmed: 11888889
Cancer Res. 2005 Jun 15;65(12):5009-14
pubmed: 15958541
Future Sci OA. 2018 May 04;4(5):FSO300
pubmed: 29796303
Gene Ther. 1997 Sep;4(9):961-8
pubmed: 9349433
Pharm Res. 2006 Mar;23(3):447-59
pubmed: 16525863
Pharm Res. 2002 Jul;19(7):933-8
pubmed: 12180544
Nat Biotechnol. 2011 Feb;29(2):154-7
pubmed: 21217696
J Exp Med. 2006 Oct 30;203(11):2441-50
pubmed: 17043144
Nanomedicine. 2007 Mar;3(1):32-42
pubmed: 17379167
Drug Discov Today. 2016 Jan;21(1):11-25
pubmed: 26210957
Acc Chem Res. 2015 Jun 16;48(6):1631-44
pubmed: 26032357
Hum Vaccin Immunother. 2013 Oct;9(10):2263-76
pubmed: 23921513
PLoS One. 2012;7(7):e40208
pubmed: 22808118
Mol Ther. 2008 Nov;16(11):1833-40
pubmed: 18797453
Nanotechnology. 2013 Jul 26;24(29):295101
pubmed: 23799649
Gene. 2016 Mar 1;578(1):1-6
pubmed: 26680098
Adv Drug Deliv Rev. 2021 Sep;176:113900
pubmed: 34324884
J Control Release. 2017 Nov 28;266:287-300
pubmed: 28987878
Mol Ther Nucleic Acids. 2019 Apr 15;15:26-35
pubmed: 30933724
Cancer Immunol Res. 2016 Feb;4(2):146-56
pubmed: 26659303
Bioconjug Chem. 2005 Sep-Oct;16(5):1240-5
pubmed: 16173804
Drug Deliv. 2013 Feb;20(2):57-64
pubmed: 23537464
FEBS Lett. 2005 Apr 11;579(10):2143-8
pubmed: 15811332
Expert Rev Vaccines. 2009 Sep;8(9):1251-76
pubmed: 19722897
J Phys Chem B. 2012 Dec 27;116(51):14805-16
pubmed: 23194173
Sci China Life Sci. 2017 Oct;60(10):1065-1076
pubmed: 29098631
ACS Nano. 2020 Oct 27;14(10):12522-12537
pubmed: 33034449
Lancet. 2017 Sep 23;390(10101):1511-1520
pubmed: 28754494
Int J Mol Sci. 2012;13(3):3229-3244
pubmed: 22489150
Cancer Gene Ther. 2012 May;19(5):303-11
pubmed: 22361816
Trends Mol Med. 2020 Mar;26(3):311-323
pubmed: 31699497
Cancer Immunol Immunother. 2019 May;68(5):799-812
pubmed: 30770959
Int J Pharm. 2021 May 15;601:120586
pubmed: 33839230
J Mol Med (Berl). 2020 Dec;98(12):1767-1779
pubmed: 33146744
Sci Rep. 2018 Jan 25;8(1):1616
pubmed: 29371676
Nucleic Acids Res. 2011 Mar;39(4):1419-26
pubmed: 20952402
Sci Transl Med. 2021 Sep 08;13(610):eabc7804
pubmed: 34516826
Science. 2014 Dec 19;346(6216):1533-6
pubmed: 25525251
Pharm Res. 2008 Mar;25(3):551-62
pubmed: 17912489
Br J Clin Pharmacol. 2016 Sep;82(3):659-72
pubmed: 27111518
J Immunother Cancer. 2015 Jun 16;3:26
pubmed: 26082837
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32114500
J Biomater Sci Polym Ed. 2002;13(11):1203-19
pubmed: 12518800
Soft Matter. 2008 Feb 21;4(3):544-549
pubmed: 32907218
Trends Biochem Sci. 2017 Jun;42(6):483-495
pubmed: 28416269
Mol Ther. 2016 Nov;24(11):2012-2020
pubmed: 27506450
Mol Pharm. 2018 Mar 5;15(3):1142-1149
pubmed: 29433310
Int J Mol Sci. 2019 Aug 29;20(17):
pubmed: 31470511
Adv Drug Deliv Rev. 2021 Nov;178:113834
pubmed: 34492233
Gene Ther. 2003 Jun;10(12):1035-40
pubmed: 12776161
Biomater Sci. 2015 Nov;3(11):1459-65
pubmed: 26244171
Nano Lett. 2018 Jun 13;18(6):3814-3822
pubmed: 29694050
NPJ Vaccines. 2020 Feb 4;5:11
pubmed: 32047656
Phys Chem Chem Phys. 2013 Aug 7;15(29):12262-73
pubmed: 23775068
J Immunother Cancer. 2019 Feb 8;7(1):38
pubmed: 30736848